Semaglutide Improves Heart Health Markers in People Living with HIV
Semaglutide improves markers of cardiovascular risk in people with HIV.
Background
Individuals living with HIV face a significantly elevated risk of developing cardiovascular disease (CVD), a burden often compounded by chronic inflammation, antiretroviral therapy side effects, and traditional risk factors like type 2 diabetes (T2D) and obesity. This increased susceptibility contributes to higher rates of atherosclerotic cardiovascular disease (ASCVD) events in this population. This study specifically addresses the critical knowledge gap regarding whether semaglutide, a well-known GLP-1 receptor agonist, can effectively improve cardiovascular risk markers in people with HIV, offering a potential new therapeutic avenue.
Study Design
Population
Individuals living with HIV who face an elevated risk of cardiovascular disease, often compounded by chronic inflammation, antiretroviral therapy side effects, and traditional risk factors like type 2 diabetes and obesity.
Intervention
Semaglutide, a GLP-1 receptor agonist; dose, route, and duration not specified.
Outcome
Improvement in cardiovascular risk markers.